No Data
No Data
12 Health Care Stocks Moving In Monday's After-Market Session
Vor Biopharma Appoints New CFO, Enhances Leadership Team
Press Release: Vor Bio Appoints Seasoned Healthcare Institutional Investor, Han Choi, M.D., LL.M., as Chief Financial Officer
Express News | Vor Bio Appoints Seasoned Healthcare Institutional Investor, Han Choi, M.d., Ll.m., as Chief Financial Officer
Analysts Offer Insights on Healthcare Companies: SAB Biotherapeutics (SABS) and Vor Biopharma (VOR)
100% of cancer patients successfully implanted with Vor Bio (VOR.US) innovative therapy will soon enter a critical trial.
Recently, Vor Bio announced the combination of its investigational stem cell therapy tremtelectogene empogeditemcel (trem-cel) with the CD33-targeted antibody-drug conjugate (ADC) Mylotarg.